Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Diet composition alters the metabolic states of adipocytes and hepatocytes in diabetes. The effects of dipeptidyl peptidase-4 (DPP-4) inhibition on adipose tissue inflammation and fatty liver have been obscure. We investigated the extrapancreatic effects of DPP-4 inhibition on visceral fat and the liver. RESEARCH DESIGN AND METHODS: We investigated diet-induced metabolic changes in β-cell–specific glucokinase haploinsufficient (Gck+/−) diabetic mice. We challenged animals with a diet containing a combination of sucrose and oleic acid (SO) or sucrose and linoleic acid (SL). Next, we assessed the effects of a DPP-4 inhibitor, des-fluoro-sitagliptin, on adipose tissue inflammation and hepatic steatosis. RESULTS: The epididymal fat weight and serum leptin level were significantly higher in Gck+/− mice fed SL than in mice fed SO, although no significant differences in body weight or adipocyte size were noted. Compared with SO, SL increased the numbers of CD11c+ M1 macrophages and CD8+ T-cells in visceral adipose tissue and the expression of E-selectin, P-selectin, and plasminogen activator inhibitor-1 (PAI-1). DPP-4 inhibition significantly prevented adipose tissue infiltration by CD8+ T-cells and M1 macrophages and decreased the expression of PAI-1. The production of cytokines by activated T-cells was not affected by DPP-4 inhibition. Furthermore, DPP-4 inhibition prevented fatty liver in both wild-type and Gck+/− mice. DPP-4 inhibition also decreased the expressions of sterol regulatory element–binding protein-1c, stearoyl-CoA desaturase-1, and fatty acid synthase, and increased the expression of peroxisome proliferator–activated receptor-α in the liver. CONCLUSIONS: Our findings indicated that DPP-4 inhibition has extrapancreatic protective effects against diet-induced adipose tissue inflammation and hepatic steatosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies in mice reported a reduction in liver TG and histologic grade of hepatic steatosis with sitagliptin [183] but if this is a direct or indirect effect is uncertain.”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [183]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment of Huh7 and HepG2 hepatoma cells with exenatide decreased intracellular lipid accumulation [181,182] by enhancing fatty acid oxidation and reducing lipogenesis [160,161,179,183].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [183]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obesity induces a phenotypic switch in adipose tissue macrophage polarization
Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29881 · Cited by 4,664 · cited 1×
“A phenotypic switch of ATMs from an anti-inflammatory M2 polarization state to a proinflammatory M1 polarization state is thought to be responsible for the inflammatory changes in the adipose tissue (21,24).”
BackgroundCinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., Wang, S., Fortier, M., Greenberg, A. S., & Obin, M. S. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500294-jlr200 · Cited by 2,529
Nishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H., Ohsugi, M., Otsu, M., Hara, K., Ueki, K., Sugiura, S., et al. (2009) · Nature Medicine · doi:10.1038/nm.1964 · Cited by 2,230
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Hodson, L., Skeaff, C. M., & Fielding, B. A. (2008) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.03.003 · Cited by 1,309
The Opposing Effects of N-3 and n-6 Fatty Acids
Schmitz, G., & Ecker, J. (2008) · Progress in Lipid Research · doi:10.1016/j.plipres.2007.12.004 · Cited by 1,245 · cited 1×
“Linoleic acid is converted to arachidonic acid in vivo, and arachidonic acid is converted to prostaglandins, leukotrienes, and other lipid mediators by lipoxygenase or cyclooxygenase (38).”
BackgroundXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Advances in Male Contraception
Page, S. T., Amory, J. K., & Bremner, W. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0041 · Cited by 1,134
Glucolipotoxicity: fuel excess and β-cell dysfunction
Poitout, V., & Robertson, R. P. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0023 · Cited by 1,092 · cited 1×
“The combination of high levels of dietary sugars and fatty acids causes metabolic abnormalities in multiple organs (1,2).”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Because GIP receptor-deficient mice had a lower weight and a lower adiposity (43), it seems unlikely that the increase in active GIP arising from the inhibition of DPP-4 caused a reduction in visceral fat.”
Background
Cited by
Items 101–200 of 245
Watanabe, T., Tamura, Y., Kakehi, S., Funayama, T., Gastaldelli, A., Takeno, K., Kawaguchi, M., Yamamoto, R., Sato, F., Ikeda, S., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12262 · Cited by 31
MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis inob/obmice
Ohyama, T., Sato, K., Yamazaki, Y., Hashizume, H., Horiguchi, N., Kakizaki, S., Mori, M., Kusano, M., & Yamada, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.16227 · Cited by 31
Self-citationRegulation of Metabolic Disease-Associated Inflammation by Nutrient Sensors
Yamashita, A. S., Belchior, T., Lira, F. S., BISHOP, N. C., Wessner, B., Neto, J. C. R., & Festuccia, W. T. (2018) · Mediators of Inflammation · doi:10.1155/2018/8261432 · Cited by 35
Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
Sharma, A., Virmani, T., Sharma, A., Chhabra, V., Kumar, G., Pathak, K., & Alhalmi, A. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s369712 · Cited by 36
DPP-4 inhibitors: a patent review (2012 – 2014)
Costante, R., Stefanucci, A., Carradori, S., Novellino, E., & Mollica, A. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.991309 · Cited by 32
Jamaluddin, J. L., Huri, H. Z., & Vethakkan, S. R. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0010 · Cited by 33
Hu, Y., Liu, H. B., Simpson, R. W., & Dear, A. E. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-2290-8 · Cited by 34
Agrimol B suppresses adipogenesis through modulation of SIRT1-PPAR gamma signal pathway
Wang, S., Zhang, Q., Zhang, Y., Shen, C., Wang, Z., Wu, Q., Zhang, Y., Li, S., & Qiao, Y. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.078 · Cited by 32
Zhao, Y., Yang, L., & Zhou, Z. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12063 · Cited by 33
Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease
Koukias, N., Buzzetti, E., & Tsochatzis, E. A. (2017) · Minerva Endocrinology · doi:10.23736/s0391-1977.16.02567-0 · Cited by 31
Yabiku, K., Mutoh, A., Miyagi, K., & Takasu, N. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.015 · Cited by 27
Shirakawa, J., Togashi, Y., Basile, G., Okuyama, T., Inoue, R., Fernandez, M., Kyohara, M., Jesus, D. F. D., Goto, N., Zhang, W., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111436 · Cited by 27
Self-citationTarantola, E., Bertone, V., Milanesi, G., Capelli, E., Ferrigno, A., Neri, D., Vairetti, M., Barni, S., & Freitas, I. (2012) · European Journal of Histochemistry · doi:10.4081/ejh.2012.e41 · Cited by 28
Novel glucose-lowering drugs for non-alcoholic fatty liver disease
Fu, Z., Cai, X., Yang, W., Zhao, M.-M., Li, R., & Li, Y. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i1.84 · Cited by 28
Ahmed, R. H., Huri, H. Z., Al-Hamodi, Z. H., Salem, S. D., & Muniandy, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140618 · Cited by 29
Kan, H., Hyogo, H., Ochi, H., Hotta, K., Fukuhara, T., Kobayashi, T., Naeshiro, N., Honda, Y., Kawaoka, T., Tsuge, M., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12552 · Cited by 26
Lamont, B. J., & Andrikopoulos, S. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0577 · Cited by 28
McKillop, A. M., Stevenson, C. L., Moran, B. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.020 · Cited by 27
Ben‐Shlomo, S., Zvibel, I., Varol, C., Spektor, L., Shlomai, A., Santo, E. M., Halpern, Z., Oren, R., & Fishman, S. (2013) · Obesity · doi:10.1002/oby.20340 · Cited by 28
Kim, T., Kim, M. K., Cheong, Y.-H., Chae, Y., Lee, Y., Ka, S., Jung, I.-H., Shin, C.-Y., Bae, E. J., & Son, M.-H. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.11.029 · Cited by 25
Santamarina, A. B., Jamar, G., Mennitti, L. V., César, H., de Rosso, V. V., Vasconcelos, J. R., Oyama, L. M., & Pisani, L. P. (2018) · Nutrients · doi:10.3390/nu10121899 · Cited by 31
Yang, M., Yan, R., Sha, R., Wang, X., Zhou, S., Li, B., Zheng, Q., & Cao, Y. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.06.018 · Cited by 27
Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models
Kim, M.-K., Chae, Y., Ahn, G.-J., Shin, C. Y., Choi, S., Yang, E. K., Sohn, Y. S., & Son, M.-H. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0864-z · Cited by 25
Effects of Liraglutide on β-Cell-Specific Glucokinase-Deficient Neonatal Mice
Shirakawa, J., Tanami, R., Togashi, Y., Tajima, K., Orime, K., Kubota, N., Kadowaki, T., Goshima, Y., & Terauchi, Y. (2012) · Endocrinology · doi:10.1210/en.2012-1165 · Cited by 25
Self-citationSharawy, M. H., El‐Kashef, D. H., Shaaban, A. A., & El‐Agamy, D. S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108088 · Cited by 28
Impact of Dietary Fatty Acids on Macrophage Lipid Metabolism, Signaling and Function
Davanso, M. R., Crisma, A. R., Murata, G. M., Newsholme, P., & Curi, R. (2020) · Immunometabolism · doi:10.20900/immunometab20200008 · Cited by 25
Dipeptidyl-peptidase-4 inhibitors have anti-inflammatory effects in patients with type 2 diabetes
Xie, D., Wang, Q., Huang, W., & Zhao, L. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03541-0 · Cited by 25
Zheng, T., Baskota, A., Gao, Y., Chen, T., Tian, H., & Yang, F. (2014) · Metabolism · doi:10.1016/j.metabol.2014.12.004 · Cited by 23
Zheng, T., Chen, B., Yang, L., Hu, X., Zhang, X., Liu, H., & Qin, L. (2017) · Metabolism · doi:10.1016/j.metabol.2017.04.012 · Cited by 23
Vincent, R. K., Williams, D. M., & Evans, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14196 · Cited by 22
CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions
Pan, K., Ohnuma, K., Morimoto, C., & Dang, N. H. (2021) · Cureus · doi:10.7759/cureus.13495 · Cited by 22
Self-citationRole of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation
Lim, S. W., Jin, J. Z., Jin, L. G., Jin, J., & Li, C. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.6.759 · Cited by 28
Anti-diabetic drugs and NASH: from current options to promising perspectives
Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1951701 · Cited by 22
Onoyama, T., Koda, M., Okamoto, T., Kishina, M., Matono, T., Sugihara, T., & Murawaki, Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4329 · Cited by 24
Yang, L., Yuan, J., & Zhou, Z. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.01.008 · Cited by 24
Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats
Refaat, R., Sakr, A., Salama, M. A., & Sarha, A. E. (2016) · Drug Development Research · doi:10.1002/ddr.21324 · Cited by 25
Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease
Akoumianakis, I., & Antoniades, C. A. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.07.001 · Cited by 23
Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway
Shen, T., Xu, B., Lei, T., Chen, L., Zhang, C., & Ni, Z. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6554 · Cited by 26
Lee, N., Heo, Y. J., Choi, S., Jeon, J. Y., Han, S. J., Kim, D. J., KANG, Y. Y., Lee, K. W., & Kim, H. J. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.12.065 · Cited by 22
Sanon, S., Patel, R., Eshelbrenner, C., Sanon, V. P., Alhaddad, M., OLIVEROS, R. A., Pham, S. V., & CHILTON, R. J. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.035 · Cited by 21
Wang, X.-M., Yang, Y., & Wu, Y. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6459-8 · Cited by 25
Chiang, Y.-T. A., Ip, W., Shao, W., Song, Z., Chernoff, J., & Jin, T. (2014) · Endocrinology · doi:10.1210/en.2013-1743 · Cited by 22
Shirakawa, J., Okuyama, T., Kyohara, M., Yoshida, E., Togashi, Y., Tajima, K., Yamazaki, S., Kaji, M., Koganei, M., Sasaki, H., et al. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0138-4 · Cited by 23
Self-citationTakeda, K., Sawazaki, H., Takahashi, H., Yeh, Y., Jheng, H., Nomura, W., Ara, T., Takahashi, N., Seno, S., Osato, N., et al. (2018) · FEBS Open Bio · doi:10.1002/2211-5463.12498 · Cited by 23
Orime, K., Shirakawa, J., Togashi, Y., Tajima, K., Inoue, H., Nagashima, Y., & Terauchi, Y. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.12.043 · Cited by 22
Self-citationCheraghpour, M., Hatami, B., & Singal, A. G. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.09.041 · Cited by 21
Vildagliptin Can Alleviate Endoplasmic Reticulum Stress in the Liver Induced by a High Fat Diet
Ma, X., Du, W., Shao, S., Yu, C., Zhou, L., & Jing, F. (2018) · BioMed Research International · doi:10.1155/2018/5045182 · Cited by 18
Song, Y., Yang, H., Kim, J., Lee, Y., Kim, S., Do, I., & Park, C. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101806 · Cited by 18
Klimontov, V. V., Тян, Н. В., Fazullina, O. N., Myakina, N. E., Орлов, Н. Б., & Konenkov, V. I. (2016) · Terapevticheskii arkhiv · doi:10.17116/terarkh2016881035-41 · Cited by 20
AlZaim, I., Eid, A. H., Abd‐Elrahman, K. S., & EL‐Yazbi, A. F. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115337 · Cited by 16
Masuda, T., Fu, Y., Eguchi, A., Czogalla, J., Rose, M. A., Kuczkowski, A., Gerasimova, M., Feldstein, A. E., Scadeng, M., & Vallon, V. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00124.2013 · Cited by 17
Do adipose tissue macrophages promote insulin resistance or adipose tissue remodelling in humans?
Heilbronn, L. K., & Liu, B. (2014) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2014-0036 · Cited by 23
Newer perspective on the coupling between glucose-mediated signaling and β-cell functionality
Shirakawa, J., & Terauchi, Y. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0335 · Cited by 19
Self-citationGemigliptin ameliorates Western-diet-induced metabolic syndrome in mice
Choi, S. H., Leem, J., Park, S., Lee, C.-K., Park, K., & Lee, I. (2016) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2016-0026 · Cited by 17
Okuyama, T., Shirakawa, J., Tajima, K., Ino, Y., Vethe, H., Togashi, Y., Kyohara, M., Inoue, R., Miyashita, D., Li, J., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217815 · Cited by 14
Self-citationMohammed, O. A. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154833 · Cited by 14
Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity
Sameshima, A., Wada, T., Ito, T., Kashimura, A., Sawakawa, K., Yonezawa, R., Tsuneki, H., Ishii, Y., Sasahara, M., Saito, S., et al. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0239 · Cited by 16
Pharmacogenetics of new classes of antidiabetic drugs
Imamović, S., Kulo, A., & Dujić, T. (2021) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2021.5646 · Cited by 24
Davidson, M. H. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2756 · Cited by 13
Bahirat, U. A., Talwar, R., Shenoy, R. R., Nemmani, K. V. S., & Goel, R. N. (2018) · Medical Molecular Morphology · doi:10.1007/s00795-018-0200-4 · Cited by 14
Wang, Z., Park, H., & Bae, E. J. (2019) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2019.23.6.459 · Cited by 14
Aoki, K., Tajima, K., Taguri, M., & Terauchi, Y. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.011 · Cited by 12
Self-citationFasolato, S., Trevellin, E., Ruvoletto, M., Granzotto, M., Zanus, G., Boscaro, E., Babetto, E., Terrin, L., Battocchio, M., Ciscato, F., et al. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.03.014 · Cited by 12
Dokmak, A., Almeqdadi, M., Trivedi, H. D., & Krishnan, S. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i7.562 · Cited by 15
Neuropeptide Y – Its role in human performance and extreme environments
Kienast, C., Gunga, H., & Steinach, M. (2019) · REACH · doi:10.1016/j.reach.2019.100032 · Cited by 16
Kjær, M. B., George, J., Kazankov, K., & Grønbæk, H. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1817740 · Cited by 14
Bahirat, U. A., Shenoy, R. R., Talwar, R., Goel, R. N., & Nemmani, K. V. S. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.004 · Cited by 12
Translational research on human pancreatic β-cell mass expansion for the treatment of diabetes
Shirakawa, J. (2021) · Diabetology International · doi:10.1007/s13340-021-00531-4 · Cited by 12
Self-citationEfficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice
Zhou, S.-T., Cui, W., Kong, L., & Xun, Y. (2022) · Current Medical Science · doi:10.1007/s11596-022-2573-9 · Cited by 12
Wang, Q., An, Y., Zhang, L., Zhang, Y., Wang, G., & Liu, J. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01233-x · Cited by 11
Baker, D. J., Atkinson, A. M., Wilkinson, G., Coope, G., Charles, A., & Leighton, B. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12498 · Cited by 14
Jansen, H. J., Vervoort, G., van der Graaf, M., Stienstra, R., & Tack, C. J. (2012) · Clinical Endocrinology · doi:10.1111/cen.12105 · Cited by 13
Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease
Corte, C. D., Liccardo, D., Ferrari, F., Alisi, A., & Nobili, V. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.960389 · Cited by 10
Liver-Brain Axis in Sporadic Alzheimer’s Disease: Role of Ten Signature Genes in a Mouse Model
Jakhmola-Mani, R., Islam, A., & Katare, D. P. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666201209111006 · Cited by 12
Xing, X.-W., Guo, S., Liu, Y.-S., Kuang, J., Huang, Z.-W., Wang, X., & Lu, Q. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10422 · Cited by 8
Klein, T., Niessen, H. G., Ittrich, C., Mayoux, E., Mueller, H., Cheetham, S. C., Stiller, D., Kassubek, J., & Mark, M. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01629.x · Cited by 10
Sanchez, R. A., Sanabria, H. D., Santos, C. D. L., & Ramirez, A. J. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i11.1186 · Cited by 10
Younan, N., Elattar, S., Youssef, M. F., Rashed, L. A., & Estaphan, S. (2019) · Physiological Reports · doi:10.14814/phy2.14191 · Cited by 10
Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal
Nobili, V., & Sanyal, A. J. (2011) · Journal of Gastroenterology · doi:10.1007/s00535-011-0467-x · Cited by 9
New Drugs on the Block—Emerging Treatments for Nonalcoholic Steatohepatitis
Stojsavljević, S., Duvnjak, M., Virović-Jukić, L., Hrabar, D., & Duvnjak, L. S. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00057 · Cited by 9
Zha, H., Fang, D., van der Reis, A. L., Chang, K., Yang, L.-Y., Xie, J., Shi, D., Xu, Q., Li, Y., & Li, L. (2020) · BMC Microbiology · doi:10.1186/s12866-020-01827-2 · Cited by 9
Cano-Europa, E., Ortiz-Butrón, R., Camargo, E. M., Estévez-Carmona, M. M., Oliart‐Ros, R. M., Blas-Valdivia, V., & Franco-Colín, M. (2016) · Journal of Medicinal Food · doi:10.1089/jmf.2016.0019 · Cited by 9
Tanimura, Y., Aoi, W., Mizushima, K., Higashimura, Y., & Naito, Y. (2019) · Experimental Physiology · doi:10.1113/ep087449 · Cited by 8
Han, A., Park, H., Kim, G. J., Kim, B.-R., Kim, Y.-R., Park, H. H., Park, J., Jin, C. H., Kim, J. M., Kwon, S., et al. (2021) · Molecules · doi:10.3390/molecules26247547 · Cited by 9
Tajima, K., Shirakawa, J., Togashi, Y., Inoue, H., Sato, K., Orime, K., Ito, Y., Kaji, M., Sakamoto, E., Nakamura, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064633 · Cited by 8
Self-citationDecrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery
Herz, C. T., Brix, J. M., Ludvik, B. H., Schernthaner, G., & Schernthaner, G.-H. (2021) · Obesity Surgery · doi:10.1007/s11695-020-05200-0 · Cited by 9
Ohminami, H., Amo, K., Taketani, Y., Sato, K., Fukaya, M., Uebanso, T., Arai, H., Koganei, M., Sasaki, H., Yamanaka‐Okumura, H., et al. (2014) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.14-11 · Cited by 8
Self-citationLi, C., Zhao, L., Zhou, X., Wu, H., & Zhao, J. (2015) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-015-1433-2 · Cited by 8
Samson, S. L., & Bajaj, M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.032 · Cited by 7
Shigiyama, F., Hiruma, S., Hisatake, S., Shiraga, N., Ikeda, T., Hirose, T., & Kumashiro, N. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0640-4 · Cited by 6
Jin, L. G., Lim, S. W., Jin, J., Chung, B. H., & Yang, C. W. (2016) · Translational research · doi:10.1016/j.trsl.2016.03.012 · Cited by 6
Estimation of Visceral Fat and Fatty Liver Disease Using Ultrasound in Patients with Diabetes
Onitsuka, Y., Takeshima, F., Ichikawa, T., Kohno, S., & Nakao, K. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.1294 · Cited by 7
High Fat and High Cholesterol Diet Induces DPP-IV Activity in Intestinal Lymph
Toyozaki, M., Osaka, M., Kondo, K., & Yoshida, M. (2013) · Journal of Oleo Science · doi:10.5650/jos.62.201 · Cited by 5
Antiatherothrombotic Effects of Dipeptidyl Peptidase Inhibitors
Cameron-Vendrig, A., Mundil, D., & Husain, M. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0408-2 · Cited by 5
Shirakawa, J., Togashi, Y., Tajima, K., Orime, K., Kikuchi, K., Miyazaki, T., Sato, K., Kimura, M., Goshima, Y., & Terauchi, Y. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.03.017 · Cited by 5
Self-citationMarinova, D., Slavova, Y. G., Trifonova, N. E., Kostadinov, D., Maksimov, V. N., & Petrov, D. (2013) · PubMed · Cited by 4
The long and the short of interferon-gamma–inducible protein 10 in hepatitis C virus infection
Gorrell, M. D., Zekry, A., McCaughan, G. W., Lloyd, A. R., Kowdley, K. V., McCaughan, G. W., & Trautwein, C. (2011) · Hepatology · doi:10.1002/hep.24600 · Cited by 4
Plant Alkaloids with Antidiabetic Potential
Gutiérrez‐Grijalva, E. P., Contreras‐Angulo, L. A., Emus-Medina, A., & Heredia, J. B. (2021) · Springer eBooks · doi:10.1007/978-981-15-8791-7_14 · Cited by 7
Neff, K., O’Donohoe, P. K., & le Roux, C. W. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1054808 · Cited by 4
Zhou, H., Shi, T., Yan, J., Chen, X., Liao, L., Zhao, S., Fang, H., & Zhuang, R. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5128 · Cited by 5
Metadata
- Authors
- Shirakawa, J., Fujii, H., Ohnuma, K., Sato, K., Ito, Y., Kaji, M., Sakamoto, E., Koganei, M., Sasaki, H., Nagashima, Y., Amo, K., Aoki, K., Morimoto, C., Takeda, E., & Terauchi, Y.
- Affiliations
- Yokohama City University (JP)
- Keio University (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Meiji (Japan) (JP)
- Tokushima University (JP)
- Corresponding author
- Terauchi, Yasuo
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-03-22
- Volume
- 60
- Issue
- 4
- Pages
- 1246-1257
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3064098
- OpenAlex
- W2102849202
- Cited by
- 246
- References
- 49
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 8 · 2023: 5 · 2022: 11 · 2021: 16 · 2020: 11 · 2019: 13 · 2018: 27 · 2017: 10 · 2016: 26 · 2015: 23 · 2014: 31 · 2013: 29 · 2012: 21
- FWCI
- 21.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (23591315, 22650223, 22590437, 21300277, 22390200)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- DPP-4 inhibition, adipose tissue inflammation, hepatic steatosis, diet-induced obesity, visceral adipose tissue, M1 macrophages, CD8+ T cells, plasminogen activator inhibitor-1, fatty acid synthase, stearoyl-CoA desaturase 1, SREBP-1c, PPARα, linoleic acid, oleic acid, sucrose, leptin
- MeSH terms
- Exenatide, Adipose Tissue, Animals, Blood Glucose, Body Weight, Dietary Fats, Enzyme-Linked Immunosorbent Assay, Fatty Liver, Female, Glucokinase, Hypertrophy, Insulin, Interferon-gamma, Liver, Male, Peptides, Triglycerides, Tumor Necrosis Factor-alpha, Venoms, Polymerase Chain Reaction, Interleukin-10, Dipeptidyl Peptidase 4, Chemokine CCL2, Dietary Sucrose, Mice, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.